CompletedNCT01500694
Official study titleA Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316
This study has finished and is no longer accepting participants.
Multiple locations, including GrazADHDMedication studyAges 6–17
- Countries
- France, United Kingdom, Belgium, + 10 others
- Sponsor
- Shire
CompletedNCT01692782
What is this study about?Researchers compared SEP-225289 and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including EncinoADHDMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Sumitomo Pharma America, Inc.
WithdrawnNCT07169162
Official study titleA Randomized, Double-blind, Parallel, Placebo-controlled, Flexible-dose Study of ADZENYS XR-ODT™ in Children Aged 4 to Less Than 6 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
This study was withdrawn before enrollment.
In Las VegasADHDMedication studyAges 4–5
- Countries
- United States
- Sponsor
- Aytu BioPharma, Inc.
CompletedNCT00269776
Official study titleScreening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 6–12
- Countries
- Sponsor
- Alza Corporation, DE, USA
CompletedNCT00304681
Official study titleThe Effectiveness of CONCERTA® vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial
This study has finished and is no longer accepting participants.
Location not clearly listedADHDMedication studyAges 6–12
- Countries
- Sponsor
- Janssen-Ortho Inc., Canada
CompletedNCT00192023
Official study titleAn Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including AlessandriaADHDMedication studyAges 6–15
- Countries
- Italy
- Sponsor
- Eli Lilly and Company
CompletedNCT00337285
What is this study about?Researchers studied Vyvanse (lisdexamfetamine dimesylate), NRP104 to find out how it affected ADHD symptoms in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockADHDMedication studyAges 18–55
- Countries
- United States
- Sponsor
- New River Pharmaceuticals
CompletedNCT00636818
Official study titleAn Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including BeijingADHDMedication studyAges 18+
- Countries
- China, South Korea, Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT00485459
What is this study about?This study evaluated the safety and effectiveness of Atomoxetine Hydrochloride for people with ADHD.
This study has finished and is no longer accepting participants.
In TaipeiADHDMedication studyAges 6–16
- Countries
- Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT00530335
Official study titleAn Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including AichiADHDMedication studyAges 18+
- Countries
- Japan
- Sponsor
- Eli Lilly and Company
CompletedNCT00962104
Official study titleA Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study has finished and is no longer accepting participants.
Multiple locations, including AichiADHDMedication studyAges 18+
- Countries
- Japan, South Korea, Taiwan
- Sponsor
- Eli Lilly and Company
CompletedNCT00568685
Official study titleA Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Bucheon-siADHDMedication studyAges 6–18
- Countries
- South Korea
- Sponsor
- Eli Lilly and Company
